Sanofi-aventis announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favour of the approval of Multaq (dronedarone) by the US Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).
The details can be read here.
No comments:
Post a Comment